Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
Replimune Group (REPL) Narrows Q2 Loss to $0.54 Per Share as Launch Gets Underway

Replimune Group (REPL) Narrows Q2 Loss to $0.54 Per Share as Launch Gets Underway

Key Takeaways

  • Replimune Group reported a net loss of $57.1 million, or $0.54 per share, for its fiscal second quarter ended September 30, 2026, narrowing from an $83.1 million loss a year earlier.
  • The loss of $0.54 per share beat the analyst consensus estimate of roughly $0.78 per share by approximately $0.24.
  • The company recorded no product revenue during the quarter, as its first commercial shipments of TUDRIQEV began in early October.
  • Research and development (R&D) expense fell to $34.4 million, while selling, general and administrative (SG&A) expense was $21.9 million as the company built out its commercial organization.
  • Replimune ended the quarter with $307.8 million in cash and cash equivalents, expected to fund operations for more than 12 months.

Earnings Context and Why It Matters

This report marks a pivotal transition for Replimune Group, a clinical-stage biotechnology company that is now becoming a commercial enterprise. The fiscal second quarter was the first full period following the U.S. Food and Drug Administration (FDA) accelerated approval of TUDRIQEV for certain patients with advanced melanoma. Because the company operates on a March fiscal year, this quarter ended September 30, 2026, falls within its fiscal 2027. With first commercial shipments beginning in early October, investors are watching closely to see whether early launch traction and disciplined spending translate into a sustainable commercial ramp. The results also offer an early read on how the company is managing costs while scaling its sales force and manufacturing capabilities. I checked a few comparable names in the sector using Tickeron’s AI Screener to get a sense of how Replimune stacks up on key metrics.

Reported Results

Replimune Group reported a net loss of $57.1 million, or $0.54 per basic and diluted share, for its fiscal second quarter ended September 30, 2026. That compares with a net loss of $83.1 million in the prior-year period. The result came in ahead of the analyst consensus estimate, which called for a loss of approximately $0.78 per share.

The company did not record product revenue during the quarter, as its first commercial shipments of TUDRIQEV occurred in early October. Management indicated it expects to report initial product revenue in the fiscal third quarter but is not providing formal revenue guidance.

On the cost side, R&D expense was $34.4 million, down from $57.9 million a year earlier. SG&A expense was $21.9 million, down from $26.4 million, though the figure reflects increased investment tied to commercial launch readiness, field hiring, and patient support programs. Replimune ended the period with $307.8 million in cash and cash equivalents, including roughly $141 million in net proceeds from an August 2026 equity offering. From what I see, the cash position provides a solid runway as the company moves into this new phase.

Market Reaction and Investor Sentiment

Replimune shares rose sharply following the release, gaining about 12.6% to reach roughly $14.70 as investors responded to the narrower-than-expected loss and early launch commentary. Sentiment has been building since the August accelerated approval of TUDRIQEV, which shifted the narrative from clinical development to commercial execution. Management reported that TUDRIQEV was first delivered to patients on October 6, with more than 15 institutions prescribing the therapy within the initial weeks. Analysts remain focused on the pace of adoption, reimbursement dynamics, and how early orders convert into recognized revenue. The market's reaction suggests investors are encouraged by the combination of a leaner cost structure and a commercial launch that is now underway.

Forward Outlook and Key Factors to Monitor

Looking ahead, the primary focus shifts to the commercial trajectory of TUDRIQEV and how quickly initial prescribing institutions convert into repeat orders. Management highlighted a target of roughly 200 priority accounts and noted that interest is extending beyond academic centers into community practices, with more than 50 meetings held with melanoma treaters to date.

Investors should monitor early adoption metrics, including the number of accounts ordering, the pace of patient starts, and reimbursement progress. Because TUDRIQEV's revenue may be recognized over multiple quarters in some cases, reported top-line figures could lag underlying demand signals in the near term.

On the clinical front, the company continues to enroll IGNYTE-3, the Phase 3 confirmatory study of TUDRIQEV plus nivolumab, and the REVEAL study in uveal melanoma. Cost discipline will also remain in focus, given the ongoing investments in the commercial launch and clinical programs. With a cash runway of more than 12 months, the company has time to demonstrate execution, but the pace of spending relative to early revenue recognition will be a key metric for investors to watch. I’m watching this closely as the launch data starts to come in.

Exploring AI Tools for Biotech Analysis

In my view, tools like Tickeron’s AI Screener can be helpful when evaluating names in the biotechnology space. The platform lets users apply filters for technical patterns, fundamentals, trends, and AI-driven signals across thousands of stocks and ETFs. It supports customizable scans by industry, market cap, volatility, and performance metrics, which can surface comparable opportunities or help refine a watchlist. For someone following Replimune Group, it offers one way to put the company’s metrics in context with peers without manual effort. I’ve found it useful for quick checks on sector trends and breakout candidates when building out research notes.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: REPL

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


REPL in -3.74% downward trend, sliding for three consecutive days on November 20, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where REPL declined for three days, in 258 of 306 cases, the price declined further within the following month. The odds of a continued downward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for REPL moved out of overbought territory on November 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 19 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on REPL as a result. In 67 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for REPL turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 39 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.

REPL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

REPL moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for REPL crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +7.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in 183 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

The Aroon Indicator entered an Uptrend today. In 175 of 218 cases where REPL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.282) is normal, around the industry mean (3.596). P/E Ratio (-6.863) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of oncolytic immunotherapies

Industry Biotechnology

Industry
Biotechnology
Address
500 Unicorn Park Drive
Phone
+1 781 222-9600
Employees
465
Web
https://www.replimune.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.